OBJECTIVE: To test vitamin B12 plasma levels in type 2 diabetic patients treated with metformin in our area. METHODS: A cross-sectional, observational study of consecutive type 2 diabetic patients on drug treatment attending an internal medicine outpatient clinic. RESULTS: One hundred and nine patients (81 treated with metformin) were enrolled into the study. Mean time on metformin treatment was 43.5 months and mean drug dose was 1,779 mg/day. Patients treated with metformin had significantly lower vitamin B(12) plasma levels (393.5 vs. 509 pg/mL, P = .0008). Seven (8.6%) of 81 patients treated with metformin and none of the 28 patients not treated with the drug had vitamin B(12) plasma levels lower than 197 pg/mL. No correlation was found between vitamin B12 plasma levles and metformin treatment time or dosage. CONCLUSIONS: In type 2 diabetic patients, treatment with metformin is associated to lower vitamin B12 plasma levels. Vitamin B12 deficiency associated with metformin is relatively common in our area.
OBJECTIVE: To test vitamin B12 plasma levels in type 2 diabeticpatients treated with metformin in our area. METHODS: A cross-sectional, observational study of consecutive type 2 diabeticpatients on drug treatment attending an internal medicine outpatient clinic. RESULTS: One hundred and nine patients (81 treated with metformin) were enrolled into the study. Mean time on metformin treatment was 43.5 months and mean drug dose was 1,779 mg/day. Patients treated with metformin had significantly lower vitamin B(12) plasma levels (393.5 vs. 509 pg/mL, P = .0008). Seven (8.6%) of 81 patients treated with metformin and none of the 28 patients not treated with the drug had vitamin B(12) plasma levels lower than 197 pg/mL. No correlation was found between vitamin B12 plasma levles and metformin treatment time or dosage. CONCLUSIONS: In type 2 diabeticpatients, treatment with metformin is associated to lower vitamin B12 plasma levels. Vitamin B12 deficiency associated with metformin is relatively common in our area.
Authors: Vanita R Aroda; Sharon L Edelstein; Ronald B Goldberg; William C Knowler; Santica M Marcovina; Trevor J Orchard; George A Bray; David S Schade; Marinella G Temprosa; Neil H White; Jill P Crandall Journal: J Clin Endocrinol Metab Date: 2016-02-22 Impact factor: 5.958